Page last updated: 2024-10-20
taurine and Hepatitis, Alcoholic
taurine has been researched along with Hepatitis, Alcoholic in 1 studies
Hepatitis, Alcoholic: INFLAMMATION of the LIVER due to ALCOHOL ABUSE. It is characterized by NECROSIS of HEPATOCYTES, infiltration by NEUTROPHILS, and deposit of MALLORY BODIES. Depending on its severity, the inflammatory lesion may be reversible or progress to LIVER CIRRHOSIS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Glycine has been well characterized in spinal cord as an inhibitory neurotransmitter which activates a glycine-gated chloride channel (GlyR) expressed in postsynaptic membranes." | 2.40 | Glycine: a new anti-inflammatory immunonutrient. ( Bradford, B; Enomoto, N; Ikejema, K; Rose, ML; Rusyn, I; Schemmer, P; Seabra, V; Stacklewitz, RF; Thurman, RG; Wheeler, MD; Yin, M; Zhong, Z, 1999) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Wheeler, MD | 1 |
| Ikejema, K | 1 |
| Enomoto, N | 1 |
| Stacklewitz, RF | 1 |
| Seabra, V | 1 |
| Zhong, Z | 1 |
| Yin, M | 1 |
| Schemmer, P | 1 |
| Rose, ML | 1 |
| Rusyn, I | 1 |
| Bradford, B | 1 |
| Thurman, RG | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis[NCT01417481] | Phase 2 | 13 participants (Actual) | Interventional | 2012-03-31 | Terminated (stopped due to Some of the researchers finished their participation in the study.) |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|
| Glycine | -0.3908 |
| Placebo | 0.2035 |
Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|
| Glycine | -0.0819 |
| Placebo | 0.1668 |
Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|
| Glycine | -0.00007 |
| Placebo | 0.1739 |
Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) |
|---|
| Cough questionnaire score | Appetite questionnaire score | Energy questionnaire score | Body weight | Height | Heart rate | Respiratory rate | Temperature |
|---|
| Glycine | 81.1 | 89.1 | 84.6 | 101.6 | 100.5 | 103.5 | 94.8 | 100.0 |
,| Placebo | 89.1 | 132.1 | 111.5 | 103.6 | 100.5 | 98.1 | 109.0 | 100.1 |
Changes in FEV1, FEF25, and FEFmax
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) |
|---|
| Forced expiratory volume at first second (FEV1) | Forced expiratory flow at 25%FVC (FEF25) | Maximal forced expiratory flow (FEFmax, PEFR) |
|---|
| Glycine | 109.7 | 133.9 | 115.3 |
,| Placebo | 91.4 | 83.3 | 91.2 |
Changes in Other Spirometric Variables
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) |
|---|
| Forced vital capacity (FVC) | Forced expiratory flow at 75%FVC (FEF75) |
|---|
| Glycine | 104.1 | 111.8 |
,| Placebo | 100.6 | 108.9 |
Changes in Pulse Oximetry, FEV1/FVC, and FEF50.
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) |
|---|
| Peripheral oxygen saturation (SpO2) | FEV1/FVC | Forced expiratory flow at 50%FVC (FEF50) |
|---|
| Glycine | 105.2 | 105.2 | 115.5 |
,| Placebo | 98.9 | 94.9 | 93.1 |
Changes in Score for Sputum Production, Dyspnea and Global Symptoms
"To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).~In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms." (NCT01417481)
Timeframe: 8 weeks
| Intervention | Percentage of baseline (Mean) |
|---|
| Sputum questionnaire score | Dyspnea questionnaire score | Total questionnaire score |
|---|
| Glycine | 82.0 | 75.6 | 77.7 |
,| Placebo | 102.6 | 103.8 | 98.7 |
Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|
| Myeloperoxidase | IL-1 | IL-4 | IL-6 | IL-7 | IL-8 | IL-12 | IL-13 | G-CSF | IFN-gamma | MCP-1 | MIP-1beta |
|---|
| Glycine | -0.4361 | -0.1635 | 0.2964 | 0.0085 | 0.0356 | -0.1466 | 0.3203 | -0.0561 | -0.0776 | 0.3272 | -0.0836 | 0.0330 |
,| Placebo | -0.2906 | -0.0352 | 0.1470 | 0.2255 | 0.0819 | -0.2364 | 0.2603 | 0.1953 | 0.2272 | 0.3639 | 0.0472 | -0.0608 |
Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)
To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution. (NCT01417481)
Timeframe: 8 weeks
| Intervention | log (percent change) (Mean) |
|---|
| Myeloperoxidase | IL-1 | IL-2 | IL-4 | IL-5 | IL-7 | IL-8 | IL-10 | IL-12 | IL-13 | IL-17 | IFN-gamma | MCP-1 | MIP-1beta | TNF-alpha | GM-CSF |
|---|
| Glycine | 0.1294 | -0.0918 | 0.0233 | -0.0161 | 0.2498 | 0.0611 | -0.0824 | 0.0549 | 0.1675 | 0.1630 | 0.0680 | 0.0248 | 0.0042 | -0.0303 | 0.0412 | -0.0538 |
,| Placebo | 0.0669 | -0.0102 | -0.0274 | 0.0522 | 0.1304 | 0.1387 | 0.0542 | 0.0074 | 0.0677 | 0.0953 | 0.1140 | 0.0649 | 0.2608 | 0.0977 | 0.1568 | -0.0822 |
Reviews
1 review available for taurine and Hepatitis, Alcoholic
| Article | Year |
|---|
Glycine: a new anti-inflammatory immunonutrient.Cellular and molecular life sciences : CMLS, 1999, Nov-30, Volume: 56, Issue:9-10
Topics: Alcohols; Animals; Anti-Inflammatory Agents; Calcium Channels, L-Type; Chloride Channels; Cyclospori | 1999 |